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ABSTRACT 
Background: Non-vitamin K antagonist oral anticoagulants including rivaroxaban are 
widely used for stroke prevention in patients with atrial fibrillation (AF). We 
investigated the relationship between plasma biomarkers (indicative of 
thrombogenesis, fibrinolysis and inflammation) and left atrial thrombus resolution 
after rivaroxaban treatment. 
Methods: This was an ancillary analysis of the X-TRA study, which was a prospective 
interventional study evaluating the use of rivaroxaban for left atrial/left atrial 
appendage (LA/LAA) thrombus resolution in AF patients. We assessed various 
biomarkers of thrombogenesis/fibrinolysis [D-dimer, plasminogen activator inhibitor-1 
(PAI-1), prothrombin fragment 1+2 (F1,2), thrombin–antithrombin (TAT) complexes, 
von Willebrand factor (vWF)] and inflammation [high-sensitivity interleukin-6 (hsIL-6), 
and high-sensitivity C-reactive protein (hsCRP)], measured at baseline and after 6 
weeks’ of rivaroxaban treatment. 
Results: There were significant decreases in the mean levels of hsCRP, D-dimer, vWF, 
and TAT from baseline to end of treatment with rivaroxaban. Although none of the 
thrombogenesis/fibrinolysis biomarkers showed a significant relationship with 
thrombus resolution, high inflammatory biomarkers at baseline were significantly 
associated with an increased chance of the thrombus being completely resolved 
(hsIL-6) or reduced/resolved (hsCRP).  
Conclusions: Biomarkers of inflammation are significantly associated with LA/LAA 
thrombus outcomes in AF patients prospectively treated with rivaroxaban.  
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Key messages:  
Changes in the thrombogenesis/fibrinolysis biomarker levels reflected the expected 
pharmacodynamics of rivaroxaban. 
Higher levels of inflammation biomarkers were significantly associated with thrombus 
being completely resolved or reduced. 
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Introduction 
 
Patients with atrial fibrillation (AF) are at high risk of left atrial (LA) thrombus formation, 
especially in the LA appendage (LAA).(1) The prevalence of LA/LAA thrombus detected 
by transesophageal echocardiography (TEE) or computed tomography varies from 0.2% 
to 3.6%, depending on anticoagulation status and CHA2DS2-VASc score.(2-5) Patients 
with documented LA/LAA thrombus are at risk of thromboembolism with the annual 
event rate of 14%.(6) This increased propensity to thrombus formation may be related 
to a prothrombotic or hypercoagulable state, which can be quantified by systemic 
assessment of various biomarkers of thrombogenesis/fibrinolysis and inflammation(7). 
 
Oral anticoagulants (OAC) including vitamin K antagonist (VKA) and non-vitamin K 
antagonist oral anticoagulants (NOACs) are well-established for effective stroke 
prevention in AF.(8, 9) Previous studies have reported the efficacy of VKA treatment on 
LA/LAA thrombus resolution,(10-13) whereas data on NOAC treatment remains scarce. 
Single case reports and case series have shown LA/LAA thrombus resolution treated 
with dabigatran, rivaroxaban, and apixaban.(14-16) More recently, a randomized 
clinical trial was conducted for investigating safety and efficacy of dabigatran in 
patients with LA/LAA thrombus.(17) Although there are some reports about the 
effectiveness of NOACs over VKA therapy, so far current guidelines recommend that 
VKA is the only treatment in AF patients who developed LA/LAA thrombus.(18) 
Furthermore, the relationship between LA/LAA thrombus outcome and biomarkers 
such as thrombogenesis/fibrinolysis and inflammation with NOAC treatment has not 
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been rigorously examined. 
 
The X-TRA study was the first prospective interventional study designed to explore the 
use of rivaroxaban, a factor Xa inhibitor, for the resolution of LA/LAA thrombi in 
patients with non-valvular AF or atrial flutter.(19) The main X-TRA study results 
demonstrated that resolved or reduced thrombus after 6 weeks’ rivaroxaban treatment 
was identified in 60.4 % of patients and was consistent with LA/LAA thrombus 
resolution with VKA therapy. Additionally, no patients experienced stroke, noncentral 
nervous system systemic embolism, and major bleeding event during the treatment 
period and the 30-day follow-up.  
 
In the present analysis, we assessed biomarkers of thrombogenesis/fibrinolysis and 
inflammation in the X-TRA study patient population and related these biomarkers with 
LA/LAA thrombus outcomes (reduced/resolved) following rivaroxaban treatment. 
 
 
Methods 
 
Study population 
The study design of X-TRA (ClinicalTrials.gov identifier NCT01839357) has been 
previously described(19). This was a prospective, interventional, single-arm, open-label, 
multicenter study (Figure 1) where once-daily (OD) rivaroxaban (20 mg od, or 15 mg od 
in patients with creatinine clearance 15–49 mL/min) was evaluated for the resolution 
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of LA/LAA thrombi in patients with AF or atrial flutter. Patients were eligible for 
inclusion in the X-TRA study if they developed LA/LAA thrombi and had to be OAC 
naive or untreated within 1 month prior to enrollment (treatment of up to 72 hours 
with VKA, heparin, or a low molecular weight heparin was allowed before the start of 
rivaroxaban) or pretreated with VKA but at suboptimal or ineffective INR levels (i.e. INR 
< 2.0, documented with at least two consecutive measurements that were at least 24 
hours apart) within the last 6 weeks.  
 
Echocardiogram parameters at baseline and during follow-up 
Echocardiogram parameters at baseline included LAA peak emptying velocity, presence 
of spontaneous echocontrast and LA/LAA thrombus area. The presence of LA/LAA 
thrombi was assessed by TEE at baseline and after 6 weeks of treatment with 
rivaroxaban. The efficacy of treatment was evaluated according to the modification of 
the thrombus, such as resolved, reduced, unchanged, larger, or newly-detected at the 
end of treatment.  
 
Biomarkers  
The biomarker testing was performed by Covance Laboratories on behalf of Bayer AG. 
The following plasma/serum biomarkers were analysed centrally at baseline and end of 
treatment, as follows: (i) thrombogenesis/fibrinolysis biomarkers: D-dimer, 
plasminogen activator inhibitor-1 (PAI-1), prothrombin fragment 1+2 (F1,2), thrombin–
antithrombin (TAT) complexes, and von Willebrand factor (vWF), and (ii) inflammation: 
high-sensitivity interleukin-6 (hsIL-6) and high-sensitivity C-reactive protein (hsCRP).  
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The associations of demographic data and medical history on biomarker levels at 
baseline were investigated. In addition, we assessed the relationship between 
biomarker levels and echocardiogram characteristics as well as LA/LAA thrombus 
outcomes. 
 
The X-TRA study was conducted with approval from the appropriate Independent 
Ethics Committee/Institutional Review Board obtained for all participating centers 
before the start of the study, in accordance with the ethical principles of the 
Declaration of Helsinki, Good Clinical Practice (GCP) and local laws, regulations, and 
organizations, as applicable. 
 
Statistical analysis 
Relationships between biomarker values and variables of interest were analysed by 
linear and logistic regression models. Multivariate models were built under 
consideration of all clinical variables. The present analysis included 3 steps: (1) identify 
relevant covariates per each endpoint (model for each endpoint with all baseline 
demographic and medical history data) based on the Akaike information criteria (AIC), 
(2) build a base model for each endpoint with the relevant covariates (from step 1) and 
one of the biomarkers as an independent variable “univariate model”, (3) build a final 
multivariate model with the base model variables as well as all biomarkers as 
independent variables and select the best variable set based on the AIC “multivariate 
model”. Models to find the relevant covariates were built not only for the biomarkers 
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but also for the clinical endpoints. These covariates were used for further models for 
the respective biomarker and clinical endpoints. In each step, the coefficient of 
determination (R2, goodness-of-fit measure) of the model was calculated to assess the 
add-on value of the clinical variables by looking at the improvement in R2. Models for 
each biomarker separately are called univariate in this context, whereas models with 
all biomarkers included are called here multivariate. The analyses assessing the 
relationship of biomarkers to echocardiogram characteristics and primary 
endpoint-related variables were performed on the modified intention to treat (mITT) 
population who had both TEE results at baseline and the end of treatment; all other 
analyses were performed on the ITT population if the patients provided at least one 
biomarker measurement. The number of actual measurements analysed varied by 
biomarker depending upon missing data, which were due to sample not taken or not 
qualified for testing or other reasons. A significant alpha-level of 0.05 was used for all 
models. Log-transformation of biomarker level was decided upon as appropriate. All 
statistical analyses were performed using SAS system version 9.4 (SAS Institute Inc.; 
Cary, NC, USA) and R software (version 3.1.2; R Core Team 2013).  
 
 
Results 
 
The X-TRA study was conducted between August 2013 and December 2014. A total of 
60 patients were enrolled in the present study (ITT analysis), and 53 patients with 
complete TEE data available were included. The remaining 7 patients were excluded 
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from the mITT population as 4 had no TEE data at baseline available (1 patient 
withdrew from the study because of an adverse event), and 3 had no TEE data at end 
of treatment (1 patient died of acute heart failure, 1 patient emigrated to another 
country because of a war, and 1 patient was hospitalized for heart transplantation).  
  
Baseline patient characteristics, echocardiography and biomarkers   
For biomarker data descriptive statistics are given for different subgroups based on 
demographic data including sex, age, and body mass index (BMI) (Supplementary Table 
S1).  
 
Multivariate models, adjusted by selected covariates based on the AIC, demonstrated 
that demographic data had limited influence on baseline levels of the biomarkers 
examined (up to 14.9 % of explained variability of log PAI-1 at baseline, see Table 1). 
The levels of hsCRP and PAI-1 were significantly reduced for patients with arterial 
hypertension (hsCRP: geometric mean of 3.25 mg/L vs. 8.53 mg/L, t-statistic of -2.061, 
p=0.045, PAI-1: geometric mean of 11.24 mg/L vs. 22.83 mg/L, t-statistic of -3.099, 
p=0.003). The levels of hsCRP were significantly increased for patients with diabetes 
mellitus (8.87 mg/L vs. 3.15 mg/L, t-statistic of 2.369, p=0.022) (Supplementary Table 
S2). 
 
Table 2 shows the relationship between echocardiogram characteristics assessed by 
TEE and biomarker levels. On univariate analysis, there were no significant associations 
between echocardiogram parameters and biomarkers at baseline (Supplementary 
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Table S3). Multivariate analysis (Table 2) shows that low hsIL-6 levels were significantly 
associated with increased LAA peak emptying velocity at baseline (regression 
coefficient with 95% CI of -9.311 [-16.58;-2.04], p=0.021). No significant association 
between LA/LAA thrombus area and biomarker levels at baseline was found, but high 
D-dimer levels were associated with an increased chance for the presence of LAA 
spontaneous echocontrast at baseline (OR with 95% CI of 33.212 [1.09;1015.30], 
p=0.045).  
 
Changes in biomarker levels between baseline and end of treatment 
Figure 2 shows comparisons of the biomarker levels between baseline and end of 
rivaroxaban treatment. There were significant baseline-adjusted decreases in the mean 
levels of hsCRP, D-dimer, vWF, and TAT from baseline to end of treatment with 
rivaroxaban (hsCRP: -39.83%, p=0.005, D-dimer: -41.49%, p<0.001, vWF: -32.061 
percentage points, p<0.001, TAT: -35.85%, p=0.022). No significant changes were 
observed in the mean PAI-1, hsIL-6 and F1,2 levels. 
 
LA/LAA thrombus outcomes and biomarker levels 
In the present study, LA/LAA thrombi were completely resolved in 41.5% of subjects 
and were reduced or resolved in 60.4% of subjects. For the biomarker analyses, Table 3 
shows the relationship between thrombus outcomes and biomarker levels.  
 
On univariate analysis, there were no significant associations between thrombus 
outcomes and biomarker levels at baseline, as well as change in biomarker levels from 
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baseline to end of treatment (Supplementary Tables S4 and S5). On multivariate 
analysis (Table 3), high levels of inflammation biomarkers, i.e. hsIL-6 and hsCRP at 
baseline were significantly associated with thrombus being completely resolved or 
reduced (OR with 95% CI of 4.909 [1.27;19.00], p=0.021, for hsIL-6 and thrombus 
completely resolved, OR with 95% CI of 9.120 [1.16;72.00], p=0.036, for hsCRP and 
thrombus reduced or resolved). None of the thrombogenesis/fibrinolysis biomarkers at 
baseline showed a significant relationship to thrombus being completely resolved or 
reduced.  
 
 
Discussion 
 
The present analysis extends data of the X-TRA study with new findings relating 
biomarker levels to LA/LAA thrombus outcomes in AF patients prospectively treated 
with rivaroxaban. First, we demonstrate that some biomarkers of thrombogenesis/ 
fibrinolysis and inflammation are favourably affected by rivaroxaban treatment. Second, 
higher levels of inflammation biomarkers, i.e. hsIL-6 and hsCRP at baseline were 
significantly associated with thrombus being completely resolved or reduced. 
  
There is growing evidence to support a relationship between inflammation and 
AF-related thrombogenesis.(20, 21) Inflammatory biomarkers are independent 
predictors of myocardial infarction, stroke, and sudden cardiac death,(22, 23) as well as 
incident AF and AF-related thrombosis.(24-28) The underlying mechanisms linking 
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inflammation and the prothrombotic state in AF include endothelial activation/damage, 
production of tissue factor from monocytes, increased platelet activation, and 
increased expression of fibrinogen.(29, 30) Endothelial dysfunction contributes to the 
development of a pro-inflammatory and pro-thrombotic environment through the 
production of cytokines.(31) Similarly, activated inflammatory cells such as monocytes 
can trigger and sustain thrombosis through regulation of monocyte-derived gene 
expression, including interleukin-8 and monocyte chemoattractant protein-1.(32, 33)  
 
However, to the best our knowledge, the relationship between LA/LAA thrombus 
outcomes and inflammatory biomarkers has not been previously examined. The 
present study indicates that high levels of inflammatory biomarkers in AF patients with 
LA/LAA thrombus were associated with thrombus being completely resolved or 
reduced with rivaroxaban treatment. This finding is of difficult explanation, but raises 
some issues regarding the relationship between inflammation and coagulation activity. 
Recently, in addition to the well-established anticoagulant activity, direct factor Xa and 
thrombin inhibitors have been explored for their potential effects beyond 
anticoagulation, including atherosclerotic plaque stabilization through 
anti-inflammatory activities.(34, 35) There is evidence suggesting that coagulation 
protease such as factor Xa and thrombin are involved in non-hemostasis cellular 
activities like inflammation. Previous studies have demonstrated that factor Xa exhibits 
pro-inflammatory activity by stimulation of interleukin (IL)-6, IL-8, and monocyte 
chemotactic protein 1 expression in endothelial cells and leukocytes.(36) Moreover, in 
primary human umbilical endothelial cells, inhibition of factor Xa downregulated the 
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expression of thrombin-mediated pro-inflammatory cytokine through prevention of 
thrombin generation.(37) Therefore, treatment with rivaroxaban may be particularly 
beneficial in patients with high-grade inflammation. 
 
D-dimer is well known as a marker of fibrin turnover and an index of 
thrombogenesis.(38) Regarding thrombus formation in patients with AF, D-dimer levels 
are a surrogate markers for a hypercoagulable state, and has been reported to increase 
with the accumulation of clinical risk factors for thromboembolism or by the presence 
of LAA thrombus.(39) Clinical utility of D-dimer level as a reflection of the thrombus 
state and burden in patients with AF has been further supported by the findings that 
high D-dimer levels in AF were reduced by both anticoagulation and cardioversion to 
the sinus rhythm.(40) In the present study, D-dimer level at baseline was associated 
with the presence of LAA spontaneous echocontrast at baseline; however, this result 
may not be applicable to the general population, as there was a selection bias due to 
no control group without LA/LAA thrombi. Furthermore, changes in D-dimer levels 
were consistent with the expected pharmacodynamics of rivaroxaban,(41) though 
there were no significant associations between change in D-dimer levels and thrombus 
outcomes. Among the other biomarkers of thrombogenesis/fibrinolysis, there were 
also no significant associations with thrombus outcomes. There are limited data on 
biomarkers of thrombogenesis/fibrinolysis under anticoagulation therapy, but the 
findings in the present study can identify specific biomarkers that warrant further 
investigation to predict their clinical characteristics and prognosis in AF patients with 
treatment of LA/LAA thrombus with rivaroxaban. 
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Limitations 
The present study was an exploratory study with a small patient population, leading to 
insufficient number to perform multivariate analysis. Effect sizes were small and 
associations between biomarkers and clinical parameters were generally weak. Second, 
oxidative stress has been reported to play an important role in the pathogenesis of AF 
and thromboembolism.(42, 43) The present study did not include the data on 
biomarkers of oxidative stress such as GDF-15 and Nitrotyrosine, but extensive survey 
including such biomarkers must be needed in order to comprehensively assess the 
pathophysiology of AF. Third, there were no control groups without LA/LAA thrombus 
and no placebo treatment arm. Therefore, the results should be interpreted with 
caution and regarded to as hypothesis generating.   
 
 
Conclusions 
 
The present study is an ancillary analysis of the X-TRA study, which was the first 
prospective, interventional, and multicentre study examining the relationship between 
biomarkers and LA/LAA thrombus resolution with rivaroxaban. We observed a 
significant decrease of some biomarkers of thrombogenesis/fibrinolysis and 
inflammation (i.e hsCRP, D-dimer, vWF, and TAT) in AF patients with LA/LAA thrombus 
after treatment with rivaroxaban. Furthermore, biomarkers of inflammation are 
associated with LA/LAA thrombus outcomes in AF patients prospectively treated with 
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rivaroxaban.    
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Figure legends 
 
Figure 1. X-TRA study design. 
CrCl, creatinine clearance; EOT, end of treatment 
 
Figure 2. Boxplots of biomarker levels. Values at baseline and end of treatment 
(descriptive). The red circles are baseline values and the blue crosses are values for the 
end of treatment. The median is indicated as a solid horizontal line in bold; “+” 
indicates the mean; the bottom and top of the box are the first and third quartiles 
(25th and 75th percentile), therefore 50% of the observations lie within this box and 
the box length is the interquartile range; the upper and lower whiskers are at the 
lowest and highest observation if they do not exceed 1.5 times the box length 
(interquartile range).  
F1,2, prothrombin fragment 1+2; hsCRP, high-sensitivity C-reactive protein; hsIL-6, 
high-sensitivity interleukin-6; PAI-1, plasminogen activator inhibitor-1; TAT, thrombin–
antithrombin complexes; vWF, von Willebrand factor. 
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Table 1. Relationship between baseline biomarkers and demographic variables based 
on multivariate models. 
 
Biomarker Sex Age BMI R2 n 
log hsCRP    0.000 55 
log D-dimer   X 0.055 53 
vWF   X 0.056 55 
log hsIL-6    0.000 46 
log PAI-1  X X 0.149 55 
log F1,2 X  X 0.130 55 
log TAT  X  0.055 51 
 
X indicates which demographic variables were used to build the model with the 
corresponding biomarker. R2 is the coefficient of determination. 
BMI, body mass index; F1,2, prothrombin fragment 1+2; hsCRP, high-sensitivity 
C-reactive protein; hsIL-6, high-sensitivity interleukin-6; PAI-1, plasminogen activator 
inhibitor-1; TAT, thrombin–antithrombin complexes; vWF, von Willebrand factor. 
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Table 2. Multivariate models of relationships between echocardiograhic 
characteristics and biomarker levels at baseline. 
 
Linear models (continuous echocardiogram parameter) 
Echocardiogram 
parameter at 
baseline 
Biomarker  
(baseline) 
Regression  
coefficient 
95% CI p-value n 
LAA peak emptying 
velocity 
log hsCRP 4.301 [-0.41 - 9.01] 0.089 28 
log D-dimer 4.602 [-0.55 - 9.75] 0.095 28 
vWF 0.037 [-0.01 - 0.08] 0.137 28 
log hsIL-6 -9.311 [-16.58 - -2.04] 0.021 28 
log TAT -8.964 [-17.68 - -0.25] 0.057 28 
LA/LAA thrombus 
area 
log D-dimer 42.550 [-5.49 - 90.59] 0.094 31 
Logistic models (binary echocardiogram parameter) 
Echocardiogram 
parameter at baseline 
Biomarker  
(baseline) 
Regression  
coefficient 
OR 95% CI p-value n 
Presence of 
spontaneous 
echocontrast 
log hsCRP -1.172 0.310 [0.05 - 1.79] 0.190 33 
log D-dimer 3.503 33.212 [1.09 - 1015.30] 0.045 33 
log TAT 6.158 472.617 [0.54 - 411305.90] 0.075 33 
 
The table shows the results from final multivariate models for the clinical endpoints 
after Akaike information criteria-based parameter selection. In addition to above 
biomarkers other demographic data were also selected as relevant covariates in this 
selection (Congestive heart failure and prior stroke were relevant covariates with LAA 
peak emptying velocity; hypertension with LA/LAA thrombus area; BMI and diabetes 
mellitus with presence of spontaneous echocontrast). 
LA, left atrium; LAA, left atrial appendage; OR, odds ratio; CI, confidence interval.  Ac
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Table 3. Multivariate logistic models of relationships between thrombus outcomes 
and biomarker baseline levels. 
 
Thrombus outcome 
Biomarker  
(baseline) 
Regression  
coefficient 
OR 95% CI p-value n 
Thrombus complete 
resolved 
log hsIL-6 1.591 4.909 [1.27 – 19.00] 0.021 33 
vWF -0.011 0.989 [0.98 – 1.00] 0.077 33 
Thrombus reduced or 
resolved 
log hsCRP 2.210 9.120 [1.16 – 72.00] 0.036 31 
vWF -0.015 0.985 [0.97 – 1.00] 0.134 31 
 
The table shows the results from final multivariate models for the clinical endpoints 
after Akaike information criteria-based parameter selection. In addition to above 
biomarkers other demographic data were also relevant covariates as results of this 
selection (diastolic blood pressure and BMI relevant with thrombus reduced or 
resolved). 
CI, confidence interval; OR, odds ratio 
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